Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine
- PMID: 25340977
- DOI: 10.1097/FBP.0000000000000104
Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine
Abstract
Recent studies suggest the possible involvement of serotonergic and endocannabinoid systems in analgesic, anxiolytic, and anticonvulsant-like actions of paracetamol. Considering the fact that these systems play intricate roles in affective disorders, we investigated the effects of paracetamol in depression-like and compulsion-like behavior. Swiss mice (20-22 g) were subjected to forced swim, tail suspension, or marble-burying tests after an injection of paracetamol either alone or in the presence of AM251 (a CB1 antagonist), fenclonine (pCPA: a 5-HT synthesis inhibitor), AM404 (anandamide uptake inhibitor) or fluoxetine. Paracetamol dose dependently (50-400 mg/kg) decreased depressive and compulsive behaviors. These effects were comparable to those of fluoxetine (5, 10, or 20 mg/kg) and AM404 (10 or 20 mg/kg). Interestingly, fenclonine pretreatment completely abolished the effects of a 50 mg/kg dose of paracetamol. However, similar effects were not observed in AM251-pretreated mice at the same dose. In contrast, AM251 completely antagonized the effects of the 400 mg/kg dose, which was otherwise partially blocked in fenclonine-treated mice. Similar sets of results were observed with fluoxetine and AM404. Thus, it appears that paracetamol-induced antidepressant-like and anticompulsive effects may, at least partially, involve both the serotonergic and the endocannabinoid system. In addition, coadministration of paracetamol and fluoxetine/AM404 at subeffective doses produced synergistic effects, indicating that subthreshold doses of fluoxetine and paracetamol may enable better management in depression and obsessive-compulsive disorder comorbid patients.
Similar articles
-
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.Behav Brain Res. 2011 Sep 30;223(1):125-34. doi: 10.1016/j.bbr.2011.04.031. Epub 2011 Apr 28. Behav Brain Res. 2011. PMID: 21549765
-
Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.Behav Pharmacol. 2019 Apr;30(2 and 3-Spec Issue):251-259. doi: 10.1097/FBP.0000000000000468. Behav Pharmacol. 2019. PMID: 30724800
-
A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine.Eur J Pharmacol. 2012 Jun 15;685(1-3):81-90. doi: 10.1016/j.ejphar.2012.04.023. Epub 2012 Apr 20. Eur J Pharmacol. 2012. PMID: 22542657
-
Paracetamol: new vistas of an old drug.CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75. doi: 10.1111/j.1527-3458.2006.00250.x. CNS Drug Rev. 2006. PMID: 17227290 Free PMC article. Review.
-
Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action.Temperature (Austin). 2021 Mar 16;8(4):351-371. doi: 10.1080/23328940.2021.1886392. eCollection 2021. Temperature (Austin). 2021. PMID: 34901318 Free PMC article. Review.
Cited by
-
On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.Neurotox Res. 2021 Dec;39(6):2072-2097. doi: 10.1007/s12640-021-00424-z. Epub 2021 Nov 6. Neurotox Res. 2021. PMID: 34741755 Review.
-
Is Experimental Evolution of an Increased Aerobic Exercise Performance in Bank Voles Mediated by Endocannabinoid Signaling Pathway?Front Physiol. 2019 May 28;10:640. doi: 10.3389/fphys.2019.00640. eCollection 2019. Front Physiol. 2019. PMID: 31191344 Free PMC article.
-
The effect of SSRIs on unconditioned anxiety: a systematic review and meta-analysis of animal studies.Psychopharmacology (Berl). 2024 Sep;241(9):1731-1755. doi: 10.1007/s00213-024-06645-2. Epub 2024 Jul 9. Psychopharmacology (Berl). 2024. PMID: 38980348 Free PMC article.
-
Paracetamol sharpens reflection and spatial memory: a double-blind randomized controlled study in healthy volunteers.Drug Des Devel Ther. 2016 Dec 5;10:3969-3976. doi: 10.2147/DDDT.S111590. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27980393 Free PMC article. Clinical Trial.
-
The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?Cannabis Cannabinoid Res. 2019 Jun 14;4(2):77-87. doi: 10.1089/can.2018.0049. eCollection 2019. Cannabis Cannabinoid Res. 2019. PMID: 32656342 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical